Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
HIV-1 envelope glycoprotein (subtype C) (Env (subtype C))
- Target
- Env (subtype C)
- Molecular classification
- Viral glycoprotein, Envelope protein, Fusion protein (specifically for gp41), Receptor-binding protein, Other
01
Overview
HIV-1 envelope glycoprotein (Env; subtype C) is a trimeric complex consisting of gp120 and gp41 subunits, crucial for virus entry into host cells by mediating binding to CD4 and chemokine receptors CCR5 or CXCR4[1][2][4][5][6]. Subtype C is the predominant HIV-1 subtype in Southern and Eastern Africa and exhibits unique sequence and structural features in its Env proteins, such as shorter V1-V2 loops and specific V3 loop signatures, which affect infectivity, cell tropism, and susceptibility to neutralizing antibodies[2][3]. Env is the principal target for vaccine development and broadly neutralizing antibodies, but its high variability and complex glycan shield present major challenges for immunogen design and therapeutic intervention[1][5].
- Other names
- HIV-1 subtype C EnvHIV-1 gp120 (subtype C)HIV-1 gp41 (subtype C)Envelope glycoprotein gp160 (subtype C)C-HIV Env
02
Mechanism of action
Inhibition of viral entry by blocking interaction of gp120 with CD4 and chemokine co-receptors (CCR5 or CXCR4) Blockade of gp41-mediated membrane fusion Neutralization of virus by preventing attachment or fusion
03
Biological functions
Viral entry/fusion with host cellsMediation of cell tropismImmune evasion (via glycan shielding and sequence variability)Induction of neutralizing antibodies
04
Disease associations
Infection (HIV/AIDS)Immune system targeting/dysfunction
05
Safety considerations
High sequence variability and glycan shielding lead to immune escape and poor vaccine efficacyAntibody-dependent enhancement (theoretical risk)Off-target effects in vaccine development due to non-specific immune activation
06
Interacting drugs
Maraviroc (targets CCR5, a host co-receptor)
3 more in the full profile.
07
Biomarkers
Presence of anti-Env (anti-gp120, anti-gp41) antibodies as markers of infection or vaccine responseSubtype-specific Env sequence markers used for epidemiology and vaccine efficacy monitoring (e.g., V3 loop, V1-V2 loop signature sequences)CD4+ T cell count (disease monitoring, not Env-specific)
Beyond the preview
Go deeper on HIV-1 envelope glycoprotein (subtype C) (Env (subtype C)).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HIV-1 envelope glycoprotein (subtype C) (Env (subtype C)).